LTLatchezar Traykov

Latchezar Traykov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Latchezar Traykov has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 January 2003
      • Vol. 96  (1) , 47-51

    [Cognitive decline and hypertension].

    by A S Rigaud, L Traykov, O Hanon, M L Seux, F Latour, H Lenoir, M Olde-Rikkert, F Forette

    The prevalence and incidence of degenerative and vascular dementia increase exponentially with age. Several studies in recent years have implicated hypertension as a risk factor not only for vascular dementia but also for degenerative dementia such as Alzheimer's disease. This is an important finding because it suggests that the treatment of hypertension could reduce the incidence of dementia. In particular, the results of the Syst-Eur study, showing that a calcium inhibitor, nitrendipine, could reduce not only the incidence of stroke but also that of dementia, should be confirmed.

  • Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease

    by Latchezar Traykov, Anne‐Sophie Rigaud, Ludovica Caputo, Remy Couderc, Joël Coste, Jean‐Luc Michot, Jocelyne de Rotrou, Philippe Amouyel, Françoise Forette, François Boller

    Controversy exists regarding the apolipoprotein E (ApoE) ɛ4 allele association with vascular dementia (VaD), ranging from increased ɛ4 frequency, similar to that found for Alzheimer's disease (AD), to no association between the ɛ4 allele and VaD. To clarify further the relationship between ApoE alleles polymorphism and cerebrovascular disease (CVD) in demented and cognitively impaired patients, we examined the ApoE phenotypes in a sample of 280 patients: 155 with AD, 21 with VaD, 32 with mixed dementia (MD), 45 with mild cognitive impairment (MCI) but without CVD, and 27 in which vascular disease was the most probable cause of cognitive decline [vascular mild cognitive impairment (VMCI)]. Our results show that the frequency of the ApoE ɛ4 allele in patients over 70 years old with clinically diagnosed VaD and VMCI does not differ significantly from that of controls. In contrast, ApoE ɛ4 allele‐bearing individuals had greater risk of having late‐onset AD (OR=8.8; 95% Cl 3.7–21.0), or non‐vascular cognitive impairment (OR=7.0; 95% Cl 2.5–19.0).


    • 1 January 1999
      • p. S38-43

    [Neuropsychological aspects of Alzheimer's disease].

    by L Traykov, P Marcie, G Dalla Barba, F Boller

    This analysis is centered on the study of cognitive disorders in Alzheimer's Disease (AD), mainly for major neuropsychological functions. We insist on the heterogeneity of the clinical picture especially in the early stages of the illness, when deficits of episodic memory and executive functions are prevalent. We consider that studying early stages of the illness is necessary to delineate the diagnostic signs, to validate the new therapeutic experiments, to predict stages of decline.